• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆可溶性尿激酶受体水平升高,但不能区分原发性和继发性局灶节段性肾小球硬化症。

Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.

机构信息

Renal Division, Peking University First Hospital, Beijing, People's Republic of China.

出版信息

Kidney Int. 2013 Aug;84(2):366-72. doi: 10.1038/ki.2013.55. Epub 2013 Feb 27.

DOI:10.1038/ki.2013.55
PMID:23447064
Abstract

In this study, we measured soluble urokinase receptor levels, a possible permeability factor, in the plasma of patients with primary focal segmental glomerulosclerosis (FSGS) and determined their association with clinical and pathological data in 74 patients with primary FSGS. Healthy donors and patients with minimal change disease, membranous nephropathy, and secondary FSGS were used as controls. The plasma-soluble urokinase receptor levels, measured by commercial ELISA kits, of patients with primary FSGS (median: 2923, interquartile range 2205-4360 pg/ml) were significantly higher than those of patients with minimal change disease (median 2050 pg/ml), membranous nephropathy (median 2029 pg/ml), and normal individuals (median 1739 pg/ml). There was no significant difference in plasma-soluble urokinase receptor levels between the 74 patients with primary and 14 patients with secondary FSGS. The soluble urokinase receptor levels increased in the order of tip variant, to a not otherwise specified variant and a cellular variant. The soluble urokinase receptor levels were significantly but negatively correlated with creatinine clearance at presentation but positively correlated with crescent formation in patients with primary FSGS. During follow-up, receptor levels decreased significantly in patients with complete remission. Thus, plasma-soluble urokinase receptor levels did not differentiate primary and secondary FSGS, and although significantly elevated in FSGS, they showed considerable overlap with other glomerular diseases.

摘要

在这项研究中,我们测量了原发性局灶节段性肾小球硬化症(FSGS)患者血浆中的可溶性尿激酶受体水平(一种可能的通透性因子),并确定了其与 74 例原发性 FSGS 患者的临床和病理数据的关系。健康供体和微小病变性肾病、膜性肾病和继发性 FSGS 患者被用作对照。使用商业 ELISA 试剂盒测量的原发性 FSGS 患者的血浆可溶性尿激酶受体水平(中位数:2923,四分位距 2205-4360 pg/ml)明显高于微小病变性肾病(中位数 2050 pg/ml)、膜性肾病(中位数 2029 pg/ml)和正常个体(中位数 1739 pg/ml)。74 例原发性 FSGS 患者与 14 例继发性 FSGS 患者的血浆可溶性尿激酶受体水平无显著差异。可溶性尿激酶受体水平按尖端变异、未特指变异和细胞变异的顺序增加。可溶性尿激酶受体水平与原发性 FSGS 患者就诊时的肌酐清除率呈显著负相关,但与新月体形成呈正相关。在随访期间,完全缓解的患者的受体水平显著下降。因此,血浆可溶性尿激酶受体水平不能区分原发性和继发性 FSGS,尽管在 FSGS 中显著升高,但与其他肾小球疾病有相当大的重叠。

相似文献

1
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.血浆可溶性尿激酶受体水平升高,但不能区分原发性和继发性局灶节段性肾小球硬化症。
Kidney Int. 2013 Aug;84(2):366-72. doi: 10.1038/ki.2013.55. Epub 2013 Feb 27.
2
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.原发性及复发性局灶节段性肾小球硬化与血清可溶性尿激酶型纤溶酶原激活物受体水平密切相关。
Transplant Proc. 2015 Jul-Aug;47(6):1760-5. doi: 10.1016/j.transproceed.2015.03.048.
3
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.原发性局灶节段性肾小球硬化症患者的尿可溶性尿激酶受体水平升高且具有致病性。
BMC Med. 2014 May 20;12:81. doi: 10.1186/1741-7015-12-81.
4
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.局灶节段性肾小球硬化症中血清可溶性尿激酶型纤溶酶原激活物受体水平与类固醇反应性的关系
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11. doi: 10.2215/CJN.02370314. Epub 2014 Oct 15.
5
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.可溶性尿激酶受体水平与IgA肾病中的局灶节段性肾小球硬化病变相关:一项来自中国的队列研究
PLoS One. 2015 Sep 18;10(9):e0138718. doi: 10.1371/journal.pone.0138718. eCollection 2015.
6
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].[可溶性尿激酶受体血清水平在特发性与继发性局灶节段性肾小球硬化鉴别诊断中的价值]
Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272.
7
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.血清可溶性尿激酶受体水平不能区分局灶节段性肾小球硬化与儿童肾病综合征的其他病因。
Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.
8
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.鉴定原发性局灶节段性肾小球硬化的潜在生物标志物及其与移植后复发的关系。
Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.
9
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.可溶性尿激酶型纤溶酶原激活物受体不是局灶节段性肾小球硬化的临床标志物。
Kidney Int. 2014 Mar;85(3):636-40. doi: 10.1038/ki.2013.505. Epub 2014 Jan 8.
10
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.局灶节段性肾小球硬化中的可溶性尿激酶受体:科学观点综述
J Immunol Res. 2016;2016:2068691. doi: 10.1155/2016/2068691. Epub 2016 Jul 18.

引用本文的文献

1
Bioinformatic identification of COLEC12 as a diagnostic biomarker and risk factor in pediatric FSGS.生物信息学鉴定COLEC12作为儿童局灶节段性肾小球硬化的诊断生物标志物和危险因素。
Front Pediatr. 2025 Apr 1;13:1539475. doi: 10.3389/fped.2025.1539475. eCollection 2025.
2
Biomarkers to predict or measure steroid resistance in idiopathic nephrotic syndrome: A systematic review.预测或测量特发性肾病综合征中类固醇抵抗的生物标志物:一项系统综述。
PLoS One. 2025 Feb 13;20(2):e0312232. doi: 10.1371/journal.pone.0312232. eCollection 2025.
3
Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.
局灶节段性肾小球硬化及相关疾病的发病机制
Annu Rev Pathol. 2025 Jan;20(1):329-353. doi: 10.1146/annurev-pathol-051220-092001.
4
Patients with primary focal segmental glomerulosclerosis with detectable urinary CD80 are more similar to patients with minimal change disease in clinicopathological features.原发性局灶节段性肾小球硬化症患者尿 CD80 可检测者在临床病理特征上更类似于微小病变性肾病患者。
Ren Fail. 2023;45(2):2279642. doi: 10.1080/0886022X.2023.2279642. Epub 2023 Nov 9.
5
What is circulating factor disease and how is it currently explained?循环因子病是什么,目前是如何解释的?
Pediatr Nephrol. 2023 Nov;38(11):3513-3518. doi: 10.1007/s00467-023-05928-8. Epub 2023 Mar 23.
6
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体:肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
7
Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis.量化局灶节段性肾小球硬化症缓解持续时间的获益。
Nephrol Dial Transplant. 2023 Mar 31;38(4):950-960. doi: 10.1093/ndt/gfac238.
8
Biomarkers in Primary Focal Segmental Glomerulosclerosis in Optimal Diagnostic-Therapeutic Strategy.原发性局灶节段性肾小球硬化症的生物标志物在最佳诊疗策略中的应用
J Clin Med. 2022 Jun 8;11(12):3292. doi: 10.3390/jcm11123292.
9
Unveiling the Features of Mercury-Associated Minimal Change Disease: Comparison with Primary Minimal Change Disease.揭示汞相关微小病变性肾病的特征:与原发性微小病变性肾病的比较。
Kidney Dis (Basel). 2021 Mar;7(2):156-165. doi: 10.1159/000510877. Epub 2020 Sep 29.
10
Complement activation profile of patients with primary focal segmental glomerulosclerosis.原发性局灶节段性肾小球硬化症患者的补体激活谱。
PLoS One. 2020 Jun 22;15(6):e0234934. doi: 10.1371/journal.pone.0234934. eCollection 2020.